Hôpital Robert Debré
Paris, 75019, France
NCT Number: NCT07311213
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social interaction and verbal and non-verbal communication (DSM-5, 2013), affecting approximately 2% of the general population. In 5 to 40% of cases, genetic factors are identified as the cause of these disorders, with prevalence depending on the technique used (exomes and/or SNP arrays) and the associated intellectual deficit. In the majority of cases, the etiology remains unknown. Studies of microdeletions/microduplications (copy number variants) or Whole Exome Sequencing and Whole Genome Sequencing (Single Nucleotide Variants) show the involvement of numerous genes in the predisposition to autism. ASD remains a genetically heterogeneous disorder, as more than 250 genes have been associated with ASD to date.
The main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.
Identifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype/genotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of participants with ASD and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).
The objective of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of participants with ASD and their genetic substrate, as well as the underlying cognitive processes.
All of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPSCs Induced pluripotent stem cells, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.
Trial opening soon.
Get Notified2 year and older
All sexes
Interventional
Not applicable
Paris, 75019, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
● For all participants :
→As a Reminder : C07-33 inclusion criteria
● Participants with ASD.
..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.
..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders
● Adult controls and adult relatives of controls
● Controls with mental retardation
→As a Reminder : inclusion criteria C16-89
● Probands with ASD
● Controls wihout ASD
● Relatives of the probands with ASD or of controls without ASD
Exclusion criteria
o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)
o History of epileptic episodes
o Immunosuppressive treatment or known immunoinflammatory disease
→As a reminder : exclusion criteria C16-89
o Severe intellectual disability (IQ<35 or developmental age <18 months)
o Identified intellectual disorder or cognitive developmental disorder
Participation in this study requires a single visit per participant. This study only requires a blood sample (5 to 30 minutes) to be taken at the CIC at Robert-Debré Hospital, Paris 19th arrondissement.
This blood sample will enable the isolation of peripheral blood mononuclear cells (PBMCs). HIV, HCV and HBV serology will also be performed.
Time frame: Inclusion visit
Blood sample to be taken from individuals with ASD, a population of relatives, and a population of controls.
Contact information is provided by the study sponsor or research team.
Institut National de la Santé Et de la Recherche Médicale, France
Other Gov
EXPLORATIONS CELLULAIRES - CELLULES PLURIPOTENTES INDUITES DES SUJETS PRESENTANT UN TSA, DE LEURS APPARENTES, ET DE TEMOINS
Acronym: IPSC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07661823
ADHD, ADHD - Attention Deficit Disorder With Hyperactivity
Richmond, Virginia, United States
View Trial DetailsNCT07634965
Autism Disorder, Autism Spectrum Disorder
View Trial DetailsNCT07509879
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Jinan, Shandong, China
View Trial DetailsNCT07498049
Autism, Autism Disorder
Nottingham, United Kingdom
View Trial Details